Considerations During Development of a Protein A-Based Antibody Purification Process

Eric Cunningham;Harish Iyer;Felicia Henderson;James Welbb;Lynn Conley;John Hanson;Christopher Bork;

Publication

Article

January 15, 2001

BioPharm International

BioPharm International-01-01-2002

Volume15

Issue 1

Considerations During Development of a Protein A-Based Antibody Purification Process

Author(s):

Eric Cunningham,Harish Iyer

by Harish Iyer, Felicia Henderson, Eric Cunningham, James Welbb, John Hanson, Christopher Bork, and Lynn Conley, IDEC Pharmaceuticals Corporation Scale-up changes in an antibody purification process can increase final product purity, make the process more robust, and reduce processing time. This case study focuses on the initial purification step -- protein A chromatography -- and offers data collected from several years of process development work on many different antibodies.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaboration

Inside Washington: Biotechnology in the Limelight, the Year Ahead

Your Vested Interests: The War of the West

Statistics for Laboratory Method Comparison Studies

From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues

Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Considerations During Development of a Protein A-Based Antibody Purification Process

Newsletter